KEY vs TARS · P/E 13, rev $7.51B vs rev $183.0M
KeyCorp (KEY) versus Tarsus Pharmaceuticals Inc (TARS) — a side-by-side from cached financials, not a winner call.
KeyCorp (KEY) is a banks - regional company listed on US.
Tarsus Pharmaceuticals Inc (TARS) is a biotechnology company listed on NASDAQ.
Latest reported KEY revenue for 2025-12-31 was $7.51B. Net income was $1.83B. Revenue was up 62.7% from 2024-12-31 to 2025-12-31. KEY currently screens at market cap $22.64B and trailing P/E 12.8.
Latest reported TARS revenue for 2024-12-31 was $183.0M. Net income was -$115.6M. Revenue was up 948.6% from 2023-12-31 to 2024-12-31. TARS currently screens at market cap $2.66B.
KEY currently screens at market cap $22.64B and trailing P/E 12.8. TARS currently screens at market cap $2.66B.
Not investment advice. Open the KEY and TARS stock pages for the full models.
Not investment advice.